You are here

Primary tabs

InSitu Biologics

Updates

April 30
Informational Webinar - Tues. May 14th | Wed. May 15th

 

Join InSitu Biologics CEO Jim Segermark, CSO Bill Taylor and Medical Advisor Jake Hutchins MD to learn about its long-lasting and long-acting non-opiate painkiller, AnestaGel.

 

RSVP here: http://invest.insitubiologics.com/

April 25
MedCity's Pitch Perfect Contest (Video)

Earlier this week Jim and co. traveled to Chicago for MedCity's Pitch Perfect Contest. Here is his 4 minute pitch.

April 23
InSitu Biologics Overview Deck

 

An overview of InSitu Biologics in 13 slides

 

April 16
[event] 4.18.19 Biotech & The Opioid Crisis - NY, NY

We're hosting a get together to network and have Dr. Jake Hutchins MD, Executive Medical Director at M Health Ambulatory Surgery Center, discuss the advancements made within the emerging field of non-opiate, peri-operative pain management. Let us know if you'd like to attend or signup here: https://www.eventbrite.com/e/biotech-the-opioid-crisis-tickets-59748194458

 

Network, Drinks, & Appetizers | Free

 

Thursday, April 18th | 5-8 PM

Staybridge Suites, Parlour Room - New York, NY

 

Jim Segermark, CEO of InSitu Biologics

1-651-338-4801 or jim@insitubiologics.com

March 27
InSitu Biologics Update #8: Stock Reopen, Animal Market, Upcoming Events

I hope this letter finds you off to a great 2019. To receive timely information on your Company, please continue to check this Update Section as we post our news here as it happens. We post information on social media as well. I use LinkedIn; please send me an invite, message me that you are a Shareholder, and you will see the information I put out as soon as it becomes available. The Company also reports news on our InSitu BiologicsTwitterInstagram and Facebook channels; please follow us there.

 

 

Animal Care Market Opportunity

 

We have begun discussions for exclusive worldwide licensing of AniGel for the Animal Care market. AniGel is our post-operative, sustained release formulation that can be used for pets of all sizes, from the smallest of cats and dogs to the Budweiser Clydesdale’s. The annual pet care market is estimated at over $130 billion and forecasted to steadily grow through 2025. Our website has more information on the opportunity and a peer-reviewed study of AniGel (AnestaGel) compared head to head with the only product for animals on the market today, Nocita, (Exparel from Pacira).

 

 

Offering Update

We are pleased to announce a 2:1 Share Split, and that we have Qualification from the SEC to sell our shares at the price of $8.00 per share. If you are not familiar with a 2:1 Share Split, that means you have two shares for each share you previously had, now at a price of $8, as opposed to the same number of shares at $16. The Market Capitalization of InSitu Biologics is now approximately 74.5 million. This is calculated by multiplying the Total Shares in the Company (9,311,51) by the Share Price of $8.00. We are currently offering 50,000 shares at $8 per share.

 

Company Progress

We are building a pilot scale manufacturing line. Without a human hand touching our Product, we will mix all the ingredients, pump them through a pipe, and fill syringes. While everything in that process remains sterile. When this is completed and fully validated for Human Use, which has its challenges, we will be ready to begin our Phase I Clinical Study. We will provide an update on that timing at the end of Q2 2019.

Our 2018 audit by Baker Tilly Virchow Krause nears completion and will be filed in an update with the SEC. In the meantime, you can find our offering in the link below:

https://www.manhattanstreetcapital.com/insitu-biologics-0 

 

Upcoming Events

We will be hosting Prospective Investor Events in NJ on 3/28, Naples, FL on 4/8 and 4/9, NYC on 4/18, and NYC again on 5/9. Please go to our website to learn more, or contact me and I will send you or your interested contact an invitation.

 

Our events can also be found at: EventBrite.com / insitubiologics.eventbrite.com

Thank you for your investment and continued interest. Please share our story.

 

 

Jim Segermark
CEO
InSitu Biologics
Jim@insitubiologics.com
(651) 338-4801

March 20
Announced: March & April Events in New Jersey and Florida

Announcing two upcoming events:

 

Investing in Biotech: Investors for Non-Opiate Pain Solutions

Casual conversation, drinks, appetizers & NCAA Sweet 16 Hoops

Thursday, March 28th | 5-?? PM EST

D'Arcy's Tavern - Bradley Beach, NJ

RSVP: https://www.eventbrite.com/e/investing-in-biotech-investors-for-non-opiate-pain-solutions-dinner-tickets-58183002928

 

Biotech Investment Presentation & Lunch

Monday, April 8 or Tuesday, April 9 | 11:30AM – 2:00PM EST

Naples Beach Hotel & Golf Club

RSVP: https://www.eventbrite.com/e/biotech-investment-presentation-lunch-tickets-57477709376

 

Feel free to reach out to me directly with any questions.

Jim Segermark
CEO
InSitu Biologics
Jim@insitubiologics.com
(651) 338-4801

February 13
Stock Sale Open Again February 13th - 18th 2019

The government shutdown in December and January has caused a tremendous backlog of quarterly and year-end filings for review at the SEC. Accordingly, our updated RegA+ Offering Price has not been reviewed.

 

We will once again open the current Offering for sales of shares at the price of $6.90 per share. This equates to a market capitalization of approximately $33.7 million dollars.

 

Shares can be purchased beginning at Noon EST on February 13 until Noon EST February 18, 2019. If we get clearance during this period, we will close to new investments at that time.

 

To start the investment process: https://www.manhattanstreetcapital.com/insitu-biologics-0

 

Feel free to reach out to me directly with any questions.

Jim Segermark
CEO
InSitu Biologics
Jim@insitubiologics.com
(651) 338-4801

January 30
Stock Offering Reopens: Wednesday, January 30th 12PM EST

I hope this note finds you off to a great 2019.

 

We are pleased to announce that InSitu Biologics Stock Offering will again open on Wednesday, January 30th at noon eastern for one week.

 

The government shutdown resulted in the SEC being closed. That has now created a backlog of companies for the SEC to review and InSitu Biologics new proposed share price is in that backlog. We hope to announce our new price within a couple months, but hope is not a plan.

 

The good news for investors is that we will be accepting new investments at the same $6.90 per share price beginning Wednesday, January 30th 12PM EST through Tuesday, February 5th 12PM EST. To reserve your shares now or to invest after noon on the 30th, simply click this link: https://www.manhattanstreetcapital.com/insitu-biologics-0

 

The current market capitalization for InSitu Biologics is $33.7 million, with our share price and amount of shares sold since July as follows:

 

  • Tier 1: $5.75 Share Price - Sold 275,661 Shares

 

  • Tier 2: $6.85 Share Price - Sold 42,666 Shares

 

  • Tier 3: $6.90 Share Price - Sold 94,775 Shares (open Jan. 30th - Feb. 5th)

 

  • Tier 4: TBD Share Price (opens after upcoming SEC clearance)

 

We are completing numerous pre-clinical studies, and Phase 1 AnestaGel manufacturing. We expect to have our first meeting with the FDA in the near future to discuss our Phase 1 human clinical study.

 

Thank you for taking the time to view our materials and better understand this opportunity. Consider becoming a Shareholder of InSitu Biologics by making an investment here starting Wednesday, January 30th at 12PM EST.

 

As always, I am available for questions, comments, and feedback.

Jim Segermark
CEO
InSitu Biologics
Jim@insitubiologics.com
(651) 338-4801

December 04
Over $2M in Investments Using Reg A+ Mini-IPO to Advance Non-Opioid Pain Drug Candidate into Clinical Trials

WOODBURY, Minn., Dec. 4, 2018 /Press Release/ -- InSitu Biologics, Inc., an emerging biotech company focusing on the development of AnestaGel™, has received over $2 million in investments. InSitu is believed to be in the midst of the largest Reg A+ round for a pre-revenue biotech company and anticipates investments reaching $10 million in 2019.

 

Since its Reg A+ launch, InSitu Biologics has sold-out of three SEC qualified price tiers. InSitu has since paused its Offering and will be submitting a new valuation and price qualification to the SEC to better reflect milestone achievements and business developments.

 

In pre-clinical studies, AnestaGel has proven to be a fast acting and long lasting, non-opiate painkiller, targeted for use in post-operative regional pain management and is expected to be explored for use in numerous surgical applications. Prior to the Reg A+ funding, InSitu Biologics published a peer-reviewed preclinical study in the Journal of Pain Research which found that AnestaGel:

  • Consistently lasted up to 300% longer when compared to the leading liposome-based sustained-release drug;
  • Had full nerve block beyond 72 hours (24-48 hours for liposome-based drug) and;
  • Carried 8x more painkiller than liposome-based drugs, remaining non-toxic.

"Development of non-addictive, non-opioid pain drugs lag far behind research for other diseases," said James Segermark, President and CEO. "Addiction often begins with post-operative pain management, for which there are few non-opiate solutions. Our investors understand that a change is required."

 

The Securities and Exchange Commission (SEC) Qualified InSitu on July 17, 2018, to raise up to $10 million using Reg A+. Reg A+ allows private companies to raise up to $50 million from the general public over a 12 month period. The SEC qualified Form 1-A can be found here: https://www.sec.gov/Archives/edgar/data/1723443/000147793218002887/insitu_1a.htm

 

The Company is audited by the CPA firm of Baker Tilly Virchow Krause. The Offering Circular, and ability to make an investment reservation can be found at https://www.manhattanstreetcapital.com/insitu-biologics-0

 

Forward-Looking Statements

We caution that, whether or not expressly stated, certain statements made in this news release that reflect management's expectations regarding future events and economic performance are forward-looking in nature and, accordingly, subject to risks and uncertainties. All statements other than statements of historical facts included in this release are forward-looking statements. In some cases, forward-looking statements can be identified by words such as "believe," "expect," "anticipate," "plan," "potential," "continue" or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which, in some cases, are beyond the Company's control which could, likely materially affect actual results, levels of activity, performance or achievements.

 

 

November 25
Update #3: Share Price, Speaker Panel, and News Sightings...

Our Tier 3 of 30,000 shares is nearly full and we will pause our Stock Offering on Tuesday, November 27, 2018. At that time we plan on submitting a new price and valuation to the SEC for qualification. Upon approval of the updated Stock Offering, we anticipate our offering will again be available for purchase in January, 2019. During the pause we’ll be taking reservations for the new share price.

 

In case you’ve missed it, our pricing and investments since July 17th are as follows:

 

Tier 1: 100% Filled at $5.75 Share Price | 275,661 Shares

Tier 2: 100% Filled at $6.85 Share Price | 43,126 Shares

Tier 3: 81% Filled at $6.90 Share Price | 30,000 Shares Available; [Paused on Tuesday, Nov. 27th]

 

Dr. Daniel Sipple will be at the 2018 G20 World Brain Mapping Therapeutics Summit in Buenos Aires, presenting on November 26th. The Summit aims to contribute to President Obama’s BRAIN initiative and to expand action on the current and upcoming initiatives across the G20 nations. Dr. Sipple will be a representative on the Brain and Spine Trauma and Opioid Crisis panel.

 

More props to Dr. Sipple with his mention in the Northwestern Medicine Magazine. https://magazine.nm.org/2018/11/12/progress-notes-5/

 

Dr. Jake Hutchins was interviewed about the newly FDA cleared drug, Dsuvia. Dsuvia, an opioid-based painkiller, has been a controversial FDA clearance. We agree with Dr. Jake Hutchins that "Dsuvia fills a gap that we don't have anything else to fill with". The full story and interview: http://www.startribune.com/u-doctor-in-middle-of-opioid-conflict/500756911/

 

MedCityNews, a leading healthcare innovation news source, interviewed us for their "Founders Story": https://medcitynews.com/2018/11/founders-story-insitu-biologics/

 

We will continue to report to you on a regular basis, however, please do not hesitate to drop me a line with any questions or comments. We remain focused on getting to Phase 1 with the best possible product. We expect our non-opiate, AnestaGel to be proven safe, fast acting, long lasting, injectable and smearable.

 

Regards,

James Segermark

President & CEO

InSitu Biologics, LLC

(651) 338-4801

Pages

An offering statement regarding this offering has been filed with the SEC. The SEC has qualified that offering statement, which only means that the company may make sales of the securities described by the offering statement. It does not mean that the SEC has approved, passed upon the merits or passed upon the accuracy or completeness of the information in the offering statement. You may obtain a copy of the offering circular that is part of that offering statement from the here.
You should read the offering circular before making any investment.

The offering materials may contain forward-looking statements and information relating to, among other things, Insitu Biologics, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company’s management. When used in the offering materials, the words “estimate,” “project,” “believe,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify and constitute forward-looking statements. These statements reflect management’s current views with respect to future events and are subject to risks and uncertainties that could cause the company’s actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.

Securities are offered through Sageworks Capital, LLC., a registered broker-dealer and member FINRA/SIPC. Neither InSitu Biologics, Inc. nor Sageworks Capital, LLC provides any investment advice or make any investment recommendations to any persons, ever, and no communication through this website or in any other medium should be construed as such.  

InSitu Biologics, Inc. securities are not publicly traded and are intended for investors who do not need a liquid investment. This investment is NOT a bank deposit (and thus NOT insured by the FDIC or by any other federal governmental agency), are NOT guaranteed by Sageworks Capital, LLC or InSitu Biologics, Inc., and MAY lose value. Investors must be able to afford the loss of their entire investment. 
Any financial projections or returns shown on the website are illustrative examples only, and there can be no assurance that any valuations provided are accurate or in agreement with market or industry valuations. Investors should conduct their own due diligence, not rely on the financial assumptions or estimates displayed on this website, and are encouraged to consult with a financial advisor, attorney, accountant, and any other professional that can help you to understand and assess the risks associated with any investment opportunity. Please refer to the offering circular for full details and disclosures, including a subscription agreement should you choose to invest.

Insitu Biologics, Inc. is required to pay an advisory retainer fee of $6,000, plus the same value of warrants at the respective issue price. In addition, they will pay a technology admin and service fee of $25 per investor, plus the same value of warrants at the respective issue price. As of 11/30/2018 Insitu Biologics has paid $24,000 in fees.